WO2022271201A3 - Ace2 and tmprss2 gene expression as predictive markers of covid-19 severity - Google Patents

Ace2 and tmprss2 gene expression as predictive markers of covid-19 severity Download PDF

Info

Publication number
WO2022271201A3
WO2022271201A3 PCT/US2022/011532 US2022011532W WO2022271201A3 WO 2022271201 A3 WO2022271201 A3 WO 2022271201A3 US 2022011532 W US2022011532 W US 2022011532W WO 2022271201 A3 WO2022271201 A3 WO 2022271201A3
Authority
WO
WIPO (PCT)
Prior art keywords
covid
infection
ace2
nucleic acids
subject
Prior art date
Application number
PCT/US2022/011532
Other languages
French (fr)
Other versions
WO2022271201A2 (en
Inventor
Sotiris Nikolopoulos
Michael PAPACHARLAMBOUS
Georgette ALITHINOS
Original Assignee
International Advantage, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Advantage, Inc. filed Critical International Advantage, Inc.
Publication of WO2022271201A2 publication Critical patent/WO2022271201A2/en
Publication of WO2022271201A3 publication Critical patent/WO2022271201A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of determining a prognosis of a subject with a COVID-19 infection is provided, comprising measuring the expression levels of ACE2 and TMPRSS2 nucleic acids or fragments thereof and one or more control nucleic acids or fragments thereof in a sample from the subject, comparing the expression levels of the nucleic acids, and determining the prognosis of COVID-19 infection in the subject based on altered expression of ACE2 and TMPRSS2 compared to the expression level of the one or more control nucleic acids, wherein an increase in expression is indicative that the COVID-19 infection is likely to be severe. When the COVID-19 infection is likely to be severe, the method also involves treating the subject with a therapeutically effective amount of a corticosteroid, a monoclonal antibody-based therapy, and/or an antiviral agent. Diagnostic kits and point-of-care devices for predicting the prognosis of a COVID-19 infection are also provided.
PCT/US2022/011532 2021-01-07 2022-01-07 Ace2 and tmprss2 gene expression as predictive markers of covid-19 severity WO2022271201A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163134607P 2021-01-07 2021-01-07
US63/134,607 2021-01-07

Publications (2)

Publication Number Publication Date
WO2022271201A2 WO2022271201A2 (en) 2022-12-29
WO2022271201A3 true WO2022271201A3 (en) 2023-03-23

Family

ID=84545897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/011532 WO2022271201A2 (en) 2021-01-07 2022-01-07 Ace2 and tmprss2 gene expression as predictive markers of covid-19 severity

Country Status (1)

Country Link
WO (1) WO2022271201A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286551A1 (en) * 2005-06-17 2006-12-21 Animal Health Research Institute, Council Of Agriculture, Executive Yuan RT-PCR detection for differential diagnosis of field isolates or lapinized vaccine strain of classical swine fever virus (CSFV) in samples
EP2508201A1 (en) * 2009-12-03 2012-10-10 Consejo Superior De Investigaciones Científicas (CSIC) Method for the identification of animals vaccinated against brucella
US20130085680A1 (en) * 2011-09-30 2013-04-04 Pandora Genomics, LLC System, Apparatus and Method for Evaluating Samples or Analytes Using a Point-of-Care Device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286551A1 (en) * 2005-06-17 2006-12-21 Animal Health Research Institute, Council Of Agriculture, Executive Yuan RT-PCR detection for differential diagnosis of field isolates or lapinized vaccine strain of classical swine fever virus (CSFV) in samples
EP2508201A1 (en) * 2009-12-03 2012-10-10 Consejo Superior De Investigaciones Científicas (CSIC) Method for the identification of animals vaccinated against brucella
US20130085680A1 (en) * 2011-09-30 2013-04-04 Pandora Genomics, LLC System, Apparatus and Method for Evaluating Samples or Analytes Using a Point-of-Care Device

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEIGEL ET AL.: "Remdesivir for the Treatment of Covid-19 - Final Report", N ENGL J MED, vol. 383, 5 November 2020 (2020-11-05), pages 1813 - 1826, XP055775825, DOI: 10.1056/NEJMoa2007764 *
BILINSKA KATARZYNA, JAKUBOWSKA PATRYCJA, VON BARTHELD CHRISTOPHER S., BUTOWT RAFAL: "Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age", ACS CHEMICAL NEUROSCIENCE, AMERICAN CHEMICAL SOCIETY, US, vol. 11, no. 11, 3 June 2020 (2020-06-03), US , pages 1555 - 1562, XP093050114, ISSN: 1948-7193, DOI: 10.1021/acschemneuro.0c00210 *
SAHEB SHARIF-ASKARI NARJES, SAHEB SHARIF-ASKARI FATEMEH, ALABED MASHAEL, TEMSAH MOHAMED-HANI, AL HEIALY SABA, HAMID QUTAYBA, HALWA: "Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD", MOLECULAR THERAPY- METHODS & CLINICAL DEVELOPMENT, NATURE PUBLISHING GROUP, GB, vol. 18, 1 September 2020 (2020-09-01), GB , pages 1 - 6, XP093050111, ISSN: 2329-0501, DOI: 10.1016/j.omtm.2020.05.013 *

Also Published As

Publication number Publication date
WO2022271201A2 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
Wang et al. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN
Kwok et al. Prognostic significance of minichromosome maintenance proteins in breast cancer
Sun et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer
Zhang et al. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer
Mahdavinezhad et al. Evaluation of miR-141, miR-200c, miR-30b expression and clinicopathological features of bladder cancer
Guo et al. USP28 is a potential prognostic marker for bladder cancer
Wang et al. miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance
Yang et al. Overexpression of HMGA2 in bladder cancer and its association with clinicopathologic features and prognosis: HMGA2 as a prognostic marker of bladder cancer
Guo et al. Expression profiles analysis reveals an integrated miRNA-lncRNA signature to predict survival in ovarian cancer patients with wild-type BRCA1/2
Hironaka-Mitsuhashi et al. A tissue microRNA signature that predicts the prognosis of breast cancer in young women
Bai et al. miR-205 regulates A549 cells proliferation by targeting PTEN
Cao et al. Positive expression of miR-361-5p indicates better prognosis for breast cancer patients
Luque et al. Association between low levels of serum miR-638 and atherosclerotic plaque vulnerability in patients with high-grade carotid stenosis
Liese et al. A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation
Ecke et al. miR‐199a‐3p and miR‐214‐3p improve the overall survival prediction of muscle‐invasive bladder cancer patients after radical cystectomy
Yang et al. Argonaute 2 is up-regulated in tissues of urothelial carcinoma of bladder
Shi et al. Expression of miR-1294 is downregulated and predicts a poor prognosis in gastric cancer
Wang et al. RUNX3 site-specific hypermethylation predicts papillary thyroid cancer recurrence
Wu et al. Enhanced serum methylated p16 DNAs is associated with the progression of gastric cancer
Huang et al. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival
CA2989388A1 (en) Gene signatures predictive of metastatic disease
Li et al. The decreased expression of miR-625 predicts poor prognosis of esophageal squamous cell carcinoma
Petraki et al. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer
Nadaraja et al. ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy
Park et al. Breast cancer epidemiology of the working-age female population reveals significant implications for the South Korean economy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22828912

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22828912

Country of ref document: EP

Kind code of ref document: A2